Please login to the form below

Not currently logged in
Email:
Password:

Stivarga

This page shows the latest Stivarga news and features for those working in and with pharma, biotech and healthcare.

Chi-Med goes for third IPO in Hong Kong

Chi-Med goes for third IPO in Hong Kong

It was the second VEGF inhibitor to reach the Chinese market, after Bayer’s Stivarga, and Chi-Med is partnering with Eli Lilly to commercialise the drug across China whilst also

Latest news

More from news
Approximately 12 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics